CXCR2 and acute myeloid leukemia: In addition, Schinke et al. (2015) have experimentally demonstrated that the inhibition of CXCR2 leads to decreased viability and clonogenic capacity of primary cells from AML patients, which pointed towards the use of IL8-CXCR2 pathway as novel therapeutic target28.